Pfizer’s Braftovi combination regime reduces death risk for patients with BRAF V600E mutant mCRC
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Annual EBITDA margin expands by 170 basis points
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Akums invested Rs. 272 crore in capital expenditure during FY25
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Subscribe To Our Newsletter & Stay Updated